Status:
COMPLETED
Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies
Lead Sponsor:
The Center for Rheumatic Disease, Allergy, & Immunology
Collaborating Sponsors:
AstraZeneca
Conditions:
Systemic Lupus Erythematosus
Eligibility:
FEMALE
16-50 years
Phase:
PHASE2
Brief Summary
SLE(Systemic Lupus Erythematosus) is an autoimmune disese that primarily occurs in women(9:1 compared to men). The disease is activated by genetic and environmental factors, yet the female gender is t...
Detailed Description
This is a double-blind study, involving (goal) 20 women with SLE. All will be premenopausal with regular menstrual cycles. Patients will meet at least four of the criteria of the American Colleges of ...
Eligibility Criteria
Inclusion
- Premenopausal women with SLE
- Without life-threatening manifestations
- With regular menstrual cyles not on hormones of any kind
Exclusion
- For any of the following:
- Increase of SLEDAI greater than 12
- If life-threatening manifestations occur
- If menstruation ceases
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00417430
Start Date
September 1 2004
End Date
December 1 2006
Last Update
September 22 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
4330 Wornall suite 40
Kansas City, Missouri, United States, 64111